New research from a team of genome scientists and DNA damage response experts breaks new ground in understanding the function of a protein currently limited in clinical trials for cancer treatments.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more advanced form, metabolic dysfunction-associated steatohepatitis, have emerged as the most prevalent liver diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results